Radioactive drug lutathera tested in teens with rare cancers
NCT ID NCT04711135
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a radioactive drug called Lutathera in teenagers aged 12 to 17 who have rare tumors of the digestive system or adrenal glands. The goal is to see if the drug is safe and how much radiation reaches organs. Eleven teens are taking part, and researchers are watching for side effects and measuring radiation doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (a radioactive drug given by IV)
What this could lead to
If it works, this could provide a new treatment option for teenagers with rare neuroendocrine tumors and related cancers that are hard to treat.
What could go wrong
This is a very small, early-phase study with only 11 participants, so results may not apply to all patients. The drug is radioactive and can cause side effects like kidney or bone marrow damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Berard
Lyon, France
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229-3039, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice, Poland
-
University College Hospital of London
London, United Kingdom
-
University of Kentucky
Lexington, Kentucky, 40536, United States